Lactoferrin is an iron-binding glycoprotein found in human and bovine milk that has powerful immune boosting effects. Its multifunctional role also encompasses antibacterial, antiviral, antifungal, antioxidant, and immunomodulatory activities. Neonatal units successfully use lactoferrin to help reduce infection in hospitals, and baby formulas manufactured in China are now being supplemented with lactoferrin. Being an immunomodulator, lactoferrin helps manage the inflammatory response, making it beneficial for such conditions as high cholesterol, gastrointestinal inflammation, respiratory tract inflammation and acne. Lactoferrin may also stimulate the cells responsible for bone growth.
Animal studies confirm that the combination of lactoferrin and chemotherapy is more effective than either treatment alone. Lactoferrin can therefore be used to increase the effectiveness of conventional treatments and also to prevent secondary infections. This is a significant advantage because infections secondary to immune dysfunction are a leading cause of mortality in cancer patients receiving radiation or chemotherapy treatments. Lactoferrin-ULTRA contains 89% protein by weight, a factor which makes it very beneficial for cancer patients, for whom the ability to maintain adequate nutrition is essential for a favorable prognosis. Proteins are particularly important to prevent the development of cancer cachexia, a condition characterized by weight loss, muscular atrophy, weakness, and anorexia.
Those requiring powerful immune system support and supplementary protein during weakened conditions and illness will greatly benefit from adding Lactoferrin-ULTRA to their diet.
Lactoferrin-Ultra combines an ultra-high dose of lactoferrin with whey protein isolate and a high-protein concentrate. Lactoferrin-Ultra is a source of essential and branched chain amino acids for protein synthesis and helps build antibodies and build and repair body tissues. Lactoferrin-Ultra uses cross-flow microfiltration to minimize unnecessary carbohydrate and saturated fat, while retaining all bioactive peptide subfractions.
|AOR04159||80034922||1 KG POWDER|
|Serving Size: 1 Rounded Scoop (30 g)||Amount|
|Energy||116 Calories/486 kJ|
|Calories from fat||6 Calories/25 kJ|
|Whey Protein||20 g †|
|Saturated Fat||0.6 g|
|Typical Amino Acid Profile per 30 g serving|
|Essential Amino Acids||12 g|
|Isoleucine (BCAA)||1.37 g|
|Leucine (BCAA)||2.59 g|
|Valine (BCAA)||1.42 g|
|Non-Essential Amino Acids||13 g|
|Aspartic acid||2.52 g|
|Glutamic acid||3.68 g|
†From 12.8 g of whey protein isolate (84% protein) and 12.6 g whey protein concentrate (74% protein).
Quantities represent typical values : Calories Per Gram: Fat 9 Carbohydrate 4 Protein 4
Ingredients : Cross-flow microfiltered whey protein isolate and concentrate, lactoferrin isolate, sunflower lecithin.
100% Natural Grade A
Free of Pesticides
Negative for Antibiotics
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, peanuts, sulphites, mustard, soy or eggs.
Mix 1 scoop daily with your favourite beverage or as directed by a qualified health care practitioner. Stir with a spoon for 30 seconds. Take a few hours before or after taking other medications.
Consult a health care practitioner prior to use if you are pregnant or breastfeeding, if you have liver or kidney disease, if you have been instructed to follow a low protein diet, or for use beyond 8 weeks. May cause mild gastrointestinal disturbances. Do not use if you have a milk allergy.
Targets abnormal cells
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Lactoferrin Ultra is an exceptional protein formulation based on the latest research. Thanks to its remarkable ability to stimulate the immune system, Lactoferrin Ultra offers new possibilities to patients suffering from immune dysfunction, infections and even cancer.
Advanced Whey with Loads of Lactoferrin
Lactoferrin Ultra contains a mixture of whey protein isolate and concentrate high in alpha-lactalbumin to which bovine lactoferrin has been added. The high lactoferrin content is crucial to the effectiveness of Lactoferrin Ultra. Numerous studies have documented that lactoferrin is beneficial for the immune system, that it can prevent infections, and that it is an effective anti-cancer agent. Human and bovine lactoferrin share a similar structure, amino acid sequence and biological activity. Recent research has shown that bovine lactoferrin is in fact a more potent inhibitor of certain human viruses.
Lactoferrin with Chemotherapy
Animal studies confirm that the combination of lactoferrin and chemotherapy is more effective than either treatment alone. Lactoferrin can therefore be used to increase the effectiveness of conventional treatments and also to prevent infections in cancer patients. This is a significant advantage because infections secondary to immune dysfunction are a leading cause of mortality in patients receiving radiation or chemotherapy treatments.
Increases Protein Intake
Lactoferrin Ultra contains 89% protein by weight. In cancer patients, the ability to maintain adequate nutrition is essential for a favorable prognosis, and proteins are particularly important to prevent the development of cancer cachexia, a condition characterized by weight loss, muscular atrophy, weakness and anorexia.
The health benefits associated with Lactoferrin Ultra are mediated by a variety of proteins naturally present in whey. Those proteins stimulate the immune system, provide antioxidants to the body, attack cancer cells and prevent the formation of new blood vessels which are needed for cancer growth. Lactoferrin has emerged as the most advantageous whey protein component in anticancer research. However, in order to be effective, lactoferrin is needed in large quantities.
A Powerful Antioxidant
Whey protein and lactoferrin are rich in glutathione precursors and studies have shown that they can both effectively increase glutathione levels. Glutathione is an important antioxidant that protects immune cells such as lymphocytes, T cells and NK cells from free radicals. Higher glutathione levels increase the proliferation of immune cells in the spleen. This explains why, in animals, supplementation with whey protein has been demonstrated to reduce the risk of developing colon tumors.
Stimulation of the Immune System
Research has clearly demonstrated that lactoferrin can directly stimulate the immune system. Lactoferrin stimulates the production of cytokines and immune cells, increases IL-18 levels (see figure 1), activates natural killer cells and enhances the cytotoxicity of neutrophils and macrophages. In short, lactoferrin helps to mount an effective immune response (see figure 2). Thanks to its immunostimulating effect, supplemental oral lactoferrin is effective against a broad range of tumors.
Figure 1: Immune activation in the small intestine of mice 24h after seven consecutive daily administrations of bovine lactoferrin (bLF). IFN-g potentiates the antiviral and antitumor effects of the type I interferons. IL-18 enhances NK cell activity – the cells responsible for the destruction of cancer cells.
The iron scavenging properties of lactoferrin also contribute to its anticancer effect. Free iron is a pro-oxidant and generates free radicals which can damage DNA and cause cancer. Lactoferrin binds to free iron, reducing the oxidation load in the body.
Iron is needed for bacterial growth. Lactoferrin sequesters iron, which partly explains its antibacterial activity. Animal studies have clearly demonstrated that lactoferrin reduces bacterial proliferation, preventing bacterial overgrowth in the intestines and reducing bacterial numbers in infected organs. The addition of lactoferrin to the drinking water of animals with fungal infections promotes recovery.
Lactoferrin is also effective against viruses. Other than interferon, lactoferrin is the only agent capable of reducing the presence of the hepatitis C virus in chronic hepatitis C patients. Lactoferrin also has an antiviral effect against human papillomavirus, the causative factor behind most cervical cancer cases.
A Direct Apoptotic Effect
Lactoferricin is a peptide fraction that is obtained from the digestion of lactoferrin in the stomach. Lactoferricin induces apoptosis directly in several cancerous cell lines. More specifically, lactoferricin induces apoptosis in human leukemia, lymphoma, breast, colon and ovarian cancer cells. It is thought that this induction results from an effect at the level of the mitochondrion.
Lactoferrin Inhibits Angiogenesis
The formation of new blood vessels is required for tumor growth. Lactoferrin is a potent inhibitor of angiogenesis (the formation of new blood vessels) and therefore prevents the progression and spread of tumors (see figure 3). In vitro and animal experiments have demonstrated that lactoferrin prevents angiogenesis, probably through an inhibitory effect on vascular endothelial growth factors (VEG-F).
Figure 3: Inhibition of angiogenesis by bovine lactoferrin (bLF).
Studies in cell lines have also confirmed that alpha-lactalbumin can inhibit the growth of human cancer cells. Lately, alpha-lactalbumin has received some extra attention. A form of alpha-lactalbumin that is unpaired with calcium and then paired with oleic acid (HAMLET, human alpha-lactalbumin made lethal to tumour cells) has been found to have selective and powerful tumoricidal activity. Another study showed that bovine alpha-lactalbumin was just as toxic to tumour cells as the human form. The results of the first human study using HAMLET on bladder cancer patients were very encouraging, showing cancer cell shedding and tumour size reductions.
Since glutathione levels are high in cancer cells, high glutathione is thought to contribute to cancer cell resistance to chemotherapy. A small study in 1995 administered 30g of whey protein concentrate over 6 months to patients with metastatic cancer. Of the small sample of 7 patients, 2 showed reduced glutathione and tumour regression, while 2 others showed tumour stabilization.
Initial experimental animal studies showed that bovine lactoferrin significantly inhibits colon, esophagus, lung and bladder carcinogenesis. These encouraging results led researchers to test the efficacy of recombinant human (rh) lactoferrin in cancer patients and found that rh-lactoferrin reduced their rates of tumour growth. In a preliminary trial, it was found that oral lactoferrin had an immunostimulating action at the level of the gut, inducing a systemic anti-cancer effect. Supplementation resulted in a decrease in the rate of tumor growth in 6 out of 7 patients. Tumor growth was reduced from 33.3% before treatment to 9.9% after treatment with lactoferrin for a period of 2 months (see figure 4).
In 2006, a study on 10 advanced tumour patients for whom chemotherapy had not succeeded were given up to 9 grams of lactoferrin in two week intervals. Talactoferrin was well tolerated with no toxicity. IL-8 activity was increased, disease stability increased and almost all patients had reduced tumour growth rates.
After the results obtained with rh-lactoferrin in this phase I clinical trial, the US Food and Drug Administration granted Fast Track designation to the clinical development of lactoferrin. The Fast Track designation is intended for the combination of a product and a claim that address an unmet medical need.
In 2008, a phase II clinical trial evaluated talactoferrin in 44 advanced progressive or metastatic renal cell carcinoma patients for whom conventional therapy had not worked. Patients received 1.5g talactoferrin twice daily for 12 weeks on, 2 weeks off. After 14 weeks, the progression-free survival rate was 59% with a median progression-free survival of 6.4 months and a response rate of 4.5%.
In 2010, half of a group of 36 patients with metastatic cancer given talactoferrin gained disease stability, especially those with renal cell carcinoma or non-small cell lung cancer.
Finally, two phase II double-blind placebo controlled randomized trials were published in 2011. Both studies were carried out in stage 3 non-small-cell lung cancer patients, one combined with chemotherapy and one post-chemotherapy failure. Both showed improvements in response rates, duration of response, progression-free survival rates and overall survival rates.
Bovine lactoferrin given orally at 3 g per day for a year was found to reduce the growth rates of polyp in the colon in patients 63-70 years of age. This study suggested that oral bovine lactoferrin is an excellent adjunct to scheduled surgical polyp removal in older patients.
The effects of HAMLET (human alpha-lactalbumin made lethal to tumour cells) on human cancer patients was published for the first time in 2011. Filling the bladder with a solution containing HAMLET caused the shedding of many cancer cells that had undergone death by apoptosis while regular alpha-lactalbumin did not have this effect. Surgery of tumour removal showed either reduction in tumour size or positive changes in tumour characteristics at surgery with no harmful effects to the surrounding non-cancerous tissue of the bladder. These results do not confirm the results of an in-vitro study showing that HAMLET and oleic acid on its harm some healthy primary cells in addition to tumour cells.
Whey proteins are normally used to help build muscle, as weight loss aids, meal replacements or just a way to get extra protein in the diet.
The popularity of lactoferrin on the world market has recently sky-rocketed. Due to the large amount of evidence for its use for improving the immunity in infants, it is being added to baby formulas and foods, making the demand for lactoferrin much higher than in recent years.
Lactoferrin Ultra provides all the additional immune health benefits of AOR’s Advanced Whey with 4.8g of lactoferrin per serving! This makes it the ideal supplement for those with severe illnesses that affect their ability to maintain adequate weight and health.
Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000 Nov-Dec;20(6C):4785-92.
Brinkmann CR, Thiel S, Larsen MK, Petersen TE, Jensenius JC, Heegaard CW. Preparation and comparison of cytotoxic complexes formed between oleic acid and either bovine or human α-lactalbumin. J Dairy Sci. 2011 May;94(5):2159-70.
Brock JH. The physiology of lactoferrin. Biochem Cell Biol. 2002;80(1):1-6.
Digumarti R, Wang Y, Raman G, Doval DC, Advani SH, Julka PK, Parikh PM, Patil S, Nag S, Madhavan J, Bapna A, Ranade AA, Varadhachary A, Malik R. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 2011 Jun;6(6):1098-103.
Hayes TG, Falchook GS, Varadhachary A. Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors. Invest New Drugs. 2010 Apr;28(2):156-62.
Hayes TG, Falchook GF, Varadhachary GR, Smith DP, Davis LD, Dhingra HM, Hayes BP, Varadhachary A. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs. 2006 May;24(3):233-40.
Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R, Figlin RA, Srinivas S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 1;113(1):72-7.
Kennedy RS, Konok GP, Bounous G, Baruchel S, Lee TD. The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study. Anticancer Res. 1995 Nov-Dec;15(6B):2643-9.
Kozu T, Iinuma G, Ohashi Y, Saito Y, Akasu T, Saito D, Alexander DB, Iigo M, Kakizoe T, Tsuda H. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res (Phila). 2009 Nov;2(11):975-83.
Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995 May-Jun;80(3):252-67.
Mistry N, Drobni P, Naslund J, Sunkari VG, Jenssen H, Evander M. The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res. 2007 Apr 20
Mossberg AK, Wullt B, Gustafsson L, Månsson W, Ljunggren E, Svanborg C. Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int J Cancer. 2007 Sep 15;121(6):1352-9.
Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, Wang Y, Varadhachary A, Zhu J, Malik R. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol. 2011 Nov 1;29(31):4129-36.
Parodi PW. A Role for Milk Proteins and their Peptides in Cancer Prevention. Curr Pharm Des. 2007;13(8):813-28.
Shimamura M, Yamamoto Y, Ashino H, Oikawa T, Hazato T, Tsuda H, Iigo M. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer. 2004 Aug 10;111(1):111-6.
Sternhagen LG, Allen JC. Growth rates of a human colon adenocarcinoma cell line are regulated by the milk protein alpha-lactalbumin. Adv Exp Med Biol. 2001;501:115-20.
Tsuda H, Sekine K, Fujita K, Ligo M. Cancer prevention by bovine lactoferrin and underlying mechanisms–a review of experimental and clinical studies. Biochem Cell Biol. 2002;80(1):131-6.
Tsuda H, Sekine K, Takasuka N, Toriyama-Baba H, Iigo M. Prevention of colon carcinogenesis and carcinoma metastasis by orally administered bovine lactoferrin in animals. Biofactors. 2000;12(1-4):83-8.
Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study.
J Infect Chemother. 2005 Dec;11(6):265-9.
Okuda M, Nakazawa T, Yamauchi K, Miyashiro E, Koizumi R, Booka M, Teraguchi S, Tamura Y, Yoshikawa N, Adachi Y, Imoto I.
Bovine lactoferrin (bLF) has antibacterial activity against Helicobacter pylori in vitro and is effective to suppress bacterial colonization in mice. The aim of our study was to evaluate the efficacy of orally administered bLF on H. pylori colonization in humans by a randomized, double-blind, placebo-controlled study. Fifty-nine healthy subjects positive for H. pylori infection were recruited. Subjects were randomized into two groups. The bLF group received bLF tablets at a dosage of 200 mg b.i.d. for a period of 12 weeks, and the control group received placebo tablets without bLF. The (13)C-urea breath test (UBT) was performed before, during, and at the end of administration, and again 4 weeks after administration. Positive response was defined as more than 50% decrease of the UBT value at the end of administration. Positive response was observed in 10 of 31 bLF-treated subjects (32.3%) and 1 of 28 control subjects (3.6%), indicating that the rate of positive response in the bLF group was significantly higher than that in the control group (bLF vs. control, P < 0.01). These results suggested that bLF administration is effective to suppress H. pylori colonization.
Milk and dairy products in cancer prevention: focus on bovine lactoferrin.
Mutat Res. 2000 Apr;462(2-3):227-33.
Tsuda H, Sekine K, Ushida Y, Kuhara T, Takasuka N, Iigo M, Han BS, Moore MA.
Milk and dairy products constitute an important part of the western style diet. A large number of epidemiological studies have been conducted to determine effects of consumption on cancer development but the data are largely equivocal, presumably reflecting the different included components. It has been proposed that whereas fats in general could promote tumor development, individual milk fats like conjugated linoleic acid could exert inhibitory effects. There is also considerable evidence that calcium in milk products protects against colon cancer, while promoting in the prostate through suppression of circulating levels of 1,25-dihydroxyvitamin D3. Whey protein may also be beneficial, as shown by both animal and human studies, and experimental data have demonstrated that the major component bovine lactoferrin (bLF), inhibits colon carcinogenesis in the post-initiation stage in male F344 rats treated with azoxymethane (AOM) without any overt toxicity. The incidence of adenocarcinomas in the groups receiving 2% and 0.2% bLF were thus 15% and 25%, respectively, in contrast to the 57.5% control value (P
All rights Reserved. Copyright © by AOR 2019